Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
|Videos|December 7, 2019
Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma
Author(s)Noa Biran, MD
Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.
Advertisement
Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.
Advertisement
Related to this article
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.
The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
2
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Updated NCCN Guidelines Recommend Rusfertide Across Polycythemia Vera
5